Characterizing the Inflammation Around Dental Implants: Bacterial Infection, Hypersensitivity or Both?

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

About this trial

The use of titanium dental implants has become a common modern treatment to restore teeth. Although the success rate of dental implants is high, inflammation around the dental implant still occurs. The current study will investigate if the inflammation around the implant is due to bacterial infection, hypersensitivity or both.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Received at least one functional implant (implant restored with a prothesis);

Did not receive peri-implant mucositis and peri-implantitis treatment in the past three months.

Disqualifiers

Dental records with incomplete information;

Individuals with a weak immune system or chronic disease such as diabetes, heart, lung or kidney disease;

Pregnant women;

Individuals undergoing orthodontic therapy and those who have oral piercing.

Trial population

This cross-sectional study is carried out at McGill University Health Center (MUHC)-Montreal General Hospital Oral and Maxillofacial Clinic. The electronic dental records database at the MUHC Montreal General Hospital Oral and Maxillofacial Clinic is screened to identify potentially eligible participants. Individuals who had a functional implant (implant restored with a prosthesis) placed between 2010 and 2022 were reviewed. Eligible individuals are contacted and invited to participate.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Clinical Examination

    Diagnostic test

    Clinical examination of a dental implant

  • Peri-implant crevicular fluid

    Procedure/Surgery

    Collection of a sample of peri-implant crevicular fluid

Treatment groups

40 Participants
are divided into 1 treatment group
Group A: Dental implants2 interventions

Trial outcomes

Primary outcomes

1

Levels of cytokines in peri-implant crevicular fluid associated with hypersensitivity

Measure the levels of IL-4, IL-5, and IL-13 in the peri-implant crevicular fluid to assess hypersensitivity responses between healthy implants and inflamed implants (mucositis and peri-implantitis). The measured unit is pg/ml.

Time frame
September 2022 - December 2024
2

Levels of cytokines in peri-implant crevicular fluid associated with bacterial infection

Measure the levels of IL-1α, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, TNF-α, GM-CSF, and IFN-γ in the peri-implant crevicular fluid to assess bacterial responses between healthy implants and inflamed implants (mucositis and peri-implantitis). The measured unit is pg/ml.

Time frame
September 2022 - December 2024
3

Levels of Matrix Metalloproteinases in peri-implant crevicular fluid

Measure the levels of MMP-1, MMP-2, and MMP-9 in the peri-implant crevicular fluid to assess hypersensitivity responses between healthy implants and inflamed implants (mucositis and peri-implantitis). The measured unit is pg/ml.

Time frame
September 2022 - December 2024
4

Levels of RANKL in peri-implant crevicular fluid

Measure the levels of RANKL in the peri-implant crevicular fluid to assess hypersensitivity responses between healthy implants and inflamed implants (mucositis and peri-implantitis). The measured unit is pg/ml.

Time frame
September 2022 - December 2024

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.